MARKET

MIRM

MIRM

Mirum Pharmaceuticals
NASDAQ
88.44
-0.44
-0.50%
After Hours: 88.44 0 0.00% 16:34 03/27 EDT
OPEN
89.42
PREV CLOSE
88.88
HIGH
90.18
LOW
87.57
VOLUME
946.84K
TURNOVER
--
52 WEEK HIGH
109.28
52 WEEK LOW
36.88
MARKET CAP
5.34B
P/E (TTM)
-190.0301
1D
5D
1M
3M
1Y
5Y
1D
Mirum Pharmaceuticals Is Maintained at Buy by TD Cowen
Dow Jones · 2d ago
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $125
Benzinga · 2d ago
Mirum Pharmaceuticals price target raised to $125 from $117 at TD Cowen
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Mirum Pharmaceuticals (MIRM) and NovoCure (NVCR)
TipRanks · 2d ago
Mirum Pharmaceuticals Price Target Maintained With a $130.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $130 Price Target
Benzinga · 6d ago
Weekly Report: what happened at MIRM last week (0316-0320)?
Weekly Report · 6d ago
Buy Rating on Mirum Pharmaceuticals Driven by Volixibat’s Differentiated IBAT Profile, Favorable PBC Market Dynamics, and Upside from PSC Expansion
TipRanks · 6d ago
More
About MIRM
Mirum Pharmaceuticals, Inc. is a rare disease company with a global footprint of approved products and a pipeline of investigational medicines. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.

Webull offers Mirum Pharmaceuticals Inc stock information, including NASDAQ: MIRM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIRM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MIRM stock methods without spending real money on the virtual paper trading platform.